Labcorp, a prominent clinical lab provider globally, has taken its appeal to the full Federal Circuit, arguing that a prior loss it faced in the Court concerning a patent linked to a $384 million decision in Texas is indicative of the ‘balkanization’ that has emerged in the court’s treatment of patent obviousness issues. The company’s stance highlights concern over inconsistencies in patent law application, a recurring topic among legal professionals navigating this complex field.
For further details on Labcorp’s appeal, visit the full article on Law360.